SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F20%3A00118265" target="_blank" >RIV/00216224:14160/20:00118265 - isvavai.cz</a>
Result on the web
<a href="https://ard.bmj.com/content/79/Suppl_1/69" target="_blank" >https://ard.bmj.com/content/79/Suppl_1/69</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY
Original language description
Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description